| 000 | 01658 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516053938.0 | ||
| 264 | 0 | _c20120301 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a1477-0970 | ||
| 024 | 7 |
_a10.1177/1352458511422929 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDamasceno, A | |
| 245 | 0 | 0 |
_aEarly onset of natalizumab-related progressive multifocal leukoencephalopathy. _h[electronic resource] |
| 260 |
_bMultiple sclerosis (Houndmills, Basingstoke, England) _cNov 2011 |
||
| 300 |
_a1397-8 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 | _aGlatiramer Acetate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadverse effects |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukoencephalopathy, Progressive Multifocal _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMianserin _xadministration & dosage |
| 650 | 0 | 4 | _aMirtazapine |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 | _aNatalizumab |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 | _aPlasma Exchange |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _avon Glehn, F | |
| 700 | 1 | _aMartinez, A R M | |
| 700 | 1 | _aLonghini, A L F | |
| 700 | 1 | _aDeus-Silva, L | |
| 700 | 1 | _aBrandão, C O | |
| 700 | 1 | _aSantos, L M B | |
| 700 | 1 | _aDamasceno, B P | |
| 773 | 0 |
_tMultiple sclerosis (Houndmills, Basingstoke, England) _gvol. 17 _gno. 11 _gp. 1397-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1352458511422929 _zAvailable from publisher's website |
| 999 |
_c21140714 _d21140714 |
||